HealthRX

Read the payment, not just the monthly equivalent

Semaglutide’s other subscriber totals are $374 every three months and $689 every six months. Its annual table explicitly pairs 48 weeks of medication with billing every 12 months. The from-$97 figure is a rounded annual equivalent, not a $97 monthly purchase.

Tirzepatide lists $602 every three months and $1,169 every six months, alongside the $2,123 annual subscription. Its $177 headline is likewise a rounded equivalent. The product table is more useful than older $179 navigation copy because it identifies the actual payment.

The supply and billing labels are distinct. We have not converted a four-week supply into a four-week billing cycle or assumed that 48 weeks guarantees a full calendar year of continuous medication. Confirm how the selected plan handles refills and any remaining weeks.

Renewal is a choice on longer plans

Subscribe & Save renews automatically; the refund policy says the price and interval appear before payment. Longer plans also offer one-time purchases. Cancellation stops future renewals, while dispensed medication is not returned by canceling the subscription.

That makes the one-time option worth comparing for someone unwilling to authorize another large payment. A subscriber discount has value only if the renewal arrangement suits the shopper. Save the selected plan and next-charge details rather than relying on a general starting-price banner.

The current offer is injection-focused

The current product pages identify compounded semaglutide and tirzepatide injections. They include prescribed medication, clinician review, instructions and overnight shipping, but do not confirm injection supplies as a standard inclusion. We removed the earlier oral-tablet and Ozempic recommendation because those routes were not established by the current catalog.

The website says an unsuccessful clinical approval receives a full refund. A successful prescription still needs the pharmacy’s exact formulation and instructions. Our recommendation concerns the published purchase terms; it is not an assessment of personal medical eligibility or a report of treatment experience.